secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-124563
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024
----------------------------------------------------------------------

- Cash and marketable securities $341.3M; operations funded into mid-2026.
- Q3 R&D expenses $60.6M (vs $41.6M YoY); net loss $72.5M (vs $53.0M).
- Phase 3 KOASTAL-1 navacaprant topline data expected around end of 2024.
- KOASTAL-2/3 topline data H1 2025; navacaprant Phase 2 bipolar depression data H2 2025.
- NMRA-511 Phase 1b AD agitation data H2 2025; M4 PAM IND submission expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/0000950170-24-124563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/nmra-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-124563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer